-
Mashup Score: 0
7500 Background: The Bruton’s tyrosine kinase inhibitor (BTKi) ibrutinib +/- anti-CD20 antibody obinutuzumab (IO) is a standard frontline regimen for older adults with CLL. BTKi alone do not often lead to complete response (CR) or undetectable minimal residual disease (uMRD), thus are given indefinitely. Smaller trials showed that IO plus venetoclax (IVO) can induce uMRD CRs which may allow successful discontinuation. Methods: Alliance for Clinical Trials in Oncology A041702 is a multicenter trial designed to evaluate if IVO with response-guided discontinuation of I improves progression free survival (PFS) versus IO with indefinite I in treatment-naïve, older CLL pts. IO is given in standard fashion, and in the IVO arm V is added at C3D1 and continued until C14D28. After 14 cycles, pts undergo response evaluation including CT scans and bone marrow biopsy with central MRD assessment by flow cytometry. Pts in IVO arm with uMRD CR discontinue I; all others continue I until progression or
Source: ascopubs.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1
European Geriatric Medicine – To study the application of a systematic protocol for specialized CGA in patients with lymphoma over 70 years of age. Patients were classified by level of…
Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
European Geriatric Medicine – To study the application of a systematic protocol for specialized CGA in patients with lymphoma over 70 years of age. Patients were classified by level of…
Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨🚨🚨 HOT OFF THE PRESS!!! #Frailty assessment to individualize treatment in older patients with #lymphoma European Geriatric Medicine @EuGMSSociety #lymsm #geriheme #hematology #geriatrics #MultidisciplinarTeam #PatientCenteredCare https://t.co/J4so8auQUV
-
-
Mashup Score: 0Risk of Fracture Following Front Line R-CHOP Immunochemotherapy in Older Patients with Diffuse Large B Cell Lymphoma Is Common - 7 month(s) ago
IntroductionDiffuse large B cell lymphoma (DLBCL) and osteoporotic fracture are commoner in older patients (pts). Steroids and chemotherapy are recognised as a
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
Fractures Common 1L R-CHOP in Older DLBCL Pts. Booth et al. @tobyeyre82 #ASH19 Abst 1615 https://t.co/BpbEXETMVi #lymsm #BoneHealth #geriheme largest series (n=477) to date to show clinically relevant fracture risk in older DLBCL pts specifically receiving R-CHOP in early f/u https://t.co/ehgFMfalj7
-
-
Mashup Score: 0
Introduction: Chemotherapy associated osteoporosis is a severe problem in patients with malignant diseases as it increases the risk for fractures and deteriorat
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Lymphoma (NHL). We prospectively evaluated bone remodeling pre- and post-chemotherapy in 61 patients with newly diagnosed NHL. First-line chemotherapy resulted in high bone turnover, which led to increased bone loss and reduced bone mineral density (BMD) of lumbar spine (L1-L4) and femur neck (FN). The reduction of L1-L4 and FN BMD post-chemo was more profound in males and in older patients (>55 years). Patients who received 8 cycles of chemotherapy had a greater reduction of L1-L4 and FN BMD as compared to 6 cycles. The administration of chemotherapy also resulted in a dramatic increase of bone resorption markers (CTX and TRACP-5b), bone formation markers, (bALP and Osteocalcin) and of osteoblast regulator Dickkopf-1. During study period, one patient had a pathological fracture in his right FN….
Source: journals.lww.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Increased risk of osteoporosis following commonly used first-line treatments for lymphoma: a Danish Nationwide Cohort Study - 7 month(s) ago
High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lym…
Source: www.tandfonline.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Identification of non-Hodgkin lymphoma patients at risk for treatment-related vertebral density loss and fractures - 7 month(s) ago
Osteoporosis International – Information on bone loss in treated non-Hodgkin’s lymphoma patients is limited. In this study, we used CT to analyze bone loss as well as prevalent and incident…
Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma - 7 month(s) ago
Key Points. Cumulative fracture incidence after R-CHOP in older patients (>70 years) is high (11.4% at 18 months).Bone involvement, prephase steroids, or eit
Source: ashpublications.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0High incidence of fractures after R-CHOP-like chemotherapy for aggressive B-cell non-Hodgkin lymphomas - 7 month(s) ago
Supportive Care in Cancer – Patients with non-Hodgkin lymphoma (NHL) have a median age of 67, with 70% surviving over 5 years. Chemotherapy for aggressive NHL includes cyclophosphamide,…
Source: link.springer.comCategories: Hem/Oncs, Latest HeadlinesTweet
Results of a phase 3 study of IVO vs IO for previously untreated older Pts w/ chronic lymphocytic leukemia (CLL) & impact of #COVID19 (@ALLIANCE_org A041702) - Woyach et al. #ASCO23 Abstract 7500 https://t.co/g5ExNiqWC6 #NCT03737981 #CLLsm #leusm #geriheme #COVID19nCancer